ArticleThe Prostate2013
Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes.
Article in The Prostate, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.Asian journal of andrologyTrial
- The Combined Effect of Polygenic Risk Score and Prostate Health Index in Chinese Men Undergoing Prostate Biopsy.Journal of clinical medicine · 2023Article
- Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies.Prostate cancer and prostatic diseases · 2022Review
- Prediction of clinically significant prostate cancer using polygenic risk models in Asians.Investigative and clinical urology · 2022Article
- Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer.Prostate cancer and prostatic diseases · 2021Article
- Polygenic risk score for genetic evaluation of prostate cancer risk in Asian populations: A narrative review.Investigative and clinical urology · 2021Review
- Application of metastatic biopsy based on "When, Who, Why, Where, How (4W1H)" principle in diagnosis and treatment of metastatic castration-resistance prostate cancer.Translational andrology and urology · 2021Article
- Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis.JAMA network open · 2019Article
- Prostate health index is useful for prostate cancer detecting in Chinese people.Translational cancer research · 2019Article
- Systematic evaluation of cancer-specific genetic risk score for 11 types of cancer in The Cancer Genome Atlas and Electronic Medical Records and Genomics cohorts.Cancer medicine · 2019Article
- Current progress and questions in germline genetics of prostate cancer.Asian journal of urology · 2019Review
- Validation of the novel susceptibility loci for prostate cancer in a Chinese population.Oncology letters · 2018Article
- An Integrative Genomics Approach for Associating Genome-Wide Association Studies Information With Localized and Metastatic Prostate Cancer Phenotypes.Biomarker insights · 2017Article
- Urinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: A case-control study.Scientific reports · 2016Article
- Effect of body mass index on the performance characteristics of PSA-related markers to detect prostate cancer.Scientific reports · 2016Article
- Development and external validation of a prostate health index-based nomogram for predicting prostate cancer.Scientific reports · 2015Article
- Influence of age on predictiveness of genetic risk score for prostate cancer in a Chinese hospital-based biopsy cohort.Oncotarget · 2015Article
- A genetic-based approach to personalized prostate cancer screening and treatment.Current opinion in urology · 2015Review
- The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making.BioMed research international · 2014Review
- A comparison of genetic risk score with family history for estimating prostate cancer risk.Asian journal of andrologyReview
Corrections and comments
- Erratum issuedErratum.2018
Authors and funding
16 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundAdditional prostate cancer (PCa) risk-associated single nucleotide polymorphisms (SNPs) continue to be identified. It is unclear whether addition of newly identified SNPs improves the discriminative performance of biopsy outcomes over previously established SNPs.
methodsA total of 667 consecutive patients that underwent prostate biopsy for detection of PCa at Huashan Hospital and Changhai Hospital, Shanghai, China were recruited. Genetic scores were calculated for each patient using various combinations of 29 PCa risk-associated SNPs. Performance of these genetic scores for discriminating prostate biopsy outcomes were compared using the area under a receiver operating characteristic curve (AUC).
resultsThe discriminative performance of genetic score derived from a panel of all 29 SNPs (24 previous and 5 new) was similar to that derived from the 24 previously established SNPs, the AUC of which were 0.60 and 0.61, respectively (P = 0.72). When SNPs with the strongest effect on PCa risk (ranked based on contribution to the total genetic variance from an external study) were sequentially added to the models for calculating genetic score, the AUC gradually increased and peaked at 0.62 with the top 13 strongest SNPs. Under the 13-SNP model, the PCa detection rate was 21.52%, 36.74%, and 51.98%, respectively for men with low (<0.5), intermediate (0.5-1.5), and high (>1.5) genetic score, P-trend = 9.91 × 10(-6).
conclusionGenetic score based on PCa risk-associated SNPs implicated to date is a significant predictor of biopsy outcome. Additional small-effect PCa risk-associated SNPs to be discovered in the future are unlikely to further improve predictive performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.